Avience Biomedicals share news and announcements

NSE: AVIENCEHealthcare Equipment & Supplies

Last close ₹240.00down ₹7.90 (3.19%)

Share price at the NSE close on 23 Oct 2026. Previous close ₹247.90.

Range of traded prices from listing on 25 Jun 2026 to 23 Oct 2026
₹222.00Low, 17 Jul 2026₹414.95High, 25 Jun 2026
Market cap
₹132 Cr
P/E
15.0
P/B
Shares changed
Dividend yield
Nonesince listing in Jun 2026
ROE
27.9%
Debt to equity
0.92
Volume, NSE
36,60088.5% delivered

Last results date

The last board meeting held for results; the company has not yet given notice of the next.Avience Biomedicals half-yearly results

Aug25Tue

The board met on 25 Aug 2026 to consider financial results and other business matters

Notice filed 20 Aug 2026

To consider and approve the revised consolidated financial results for the period ended March 31, 2026 and other business matters (opens in a new tab)

Avience Biomedicals annual reports, presentations and earnings calls

The company's own documents, latest first.Avience Biomedicals financials, year by year

Avience Biomedicals share news and announcements

18 announcements, routine notices left out, newest first.

  1. Oct 2026

  2. Sep 2026

  3. Aug 2026

  4. Jul 2026

How the price met the news

The first session after each announcement, beside the market.

That dayAgainst the Nifty 500Market median on that newsFive sessionsFive sessions against the Nifty 500Volume, times usual

Avience Biomedicals results filing dates and deadlines

Listed companies must file half-yearly results within 45 days, and the year's within 60.

Days to fileDeadline

  • Year to Mar 2026Board met 16 Jul 2026, notice given 14 Jul 2026108 days of 107After the deadline
  • Half year to Mar 2026Board met 16 Jul 2026, notice given 14 Jul 2026108 days of 107After the deadline

Figures filed again

Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.

LinePeriodAccountsFirst filedFiled againFirst filed onFiled again on
Assets turning to cash within a yearAt Mar 2026Consolidated46.5443.16−7.3%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Total assetsAt Mar 2026Consolidated77.9474.57−4.3%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Other liabilities due within a yearAt Mar 2026Consolidated4.431.05−76.2%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Liabilities due within a yearAt Mar 2026Consolidated32.9629.58−10.2%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Total equity and liabilitiesAt Mar 2026Consolidated77.9474.57−4.3%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Change in other current assetsYear to Mar 2026Consolidated−1.801.58+187.8%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Change in other current liabilitiesYear to Mar 2026Consolidated1.33−2.05−254.2%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Items whose cash is in investing or financingYear to Mar 2026Consolidated1.35−0.08−105.8%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Adjustments from profit to cashYear to Mar 2026Consolidated−3.69−3.690.0%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)
Cash generated before taxYear to Mar 2026Consolidated8.788.780.0%17 Jul 2026 (opens in a new tab)26 Aug 2026 (opens in a new tab)